Novo Nordisk Investigational Site

Campinas, São Paulo 13081970

0 studies enrolling now · 11 studies all time

What they study most

Congenital Bleeding Disorder, Diabetes, Diabetes Mellitus, Type 2, Haemophilia A, Haemophilia A With Inhibitors, Haemophilia B, Haemophilia B With Inhibitors, Metabolism and Nutrition Disorder, Obesity

Studies at this site

• A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia A — Completed
• Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A — Completed
• Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A — Completed
• Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A. — Completed
• Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results — Completed
• Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes — Completed
• Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes — Completed
• Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015 — Completed
• Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A — Completed
• Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds — Completed
• Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia — Completed